Cytoplasmic CD79a is a promising biomarker for B lymphoblastic leukemia follow up post CD19 CAR-T therapy

Man Chena Department of Laboratory Medicine, Hebei Yanda Lu Daopei Hospital, Langfang, China

Minjing Fua Department of Laboratory Medicine, Hebei Yanda Lu Daopei Hospital, Langfang, China

Aixian Wanga Department of Laboratory Medicine, Hebei Yanda Lu Daopei Hospital, Langfang, China

Xueying Wua Department of Laboratory Medicine, Hebei Yanda Lu Daopei Hospital, Langfang, China

Junyi Zhena Department of Laboratory Medicine, Hebei Yanda Lu Daopei Hospital, Langfang, China

Meiwei Gonga Department of Laboratory Medicine, Hebei Yanda Lu Daopei Hospital, Langfang, China

Xian Zhangb Department of Haematology, Hebei Yanda Lu Daopei Hospital, Langfang, China

Guanlan Yuec Department of Stem Cell Transplantation, Hebei Yanda Lu Daopei Hospital, Langfang, China

Qing Dua Department of Laboratory Medicine, Hebei Yanda Lu Daopei Hospital, Langfang, China

Wei Zhaoc Department of Stem Cell Transplantation, Hebei Yanda Lu Daopei Hospital, Langfang, China

Yanli Zhaoc Department of Stem Cell Transplantation, Hebei Yanda Lu Daopei Hospital, Langfang, China

Peihua Luc Department of Stem Cell Transplantation, Hebei Yanda Lu Daopei Hospital, Langfang, China

Hui Wanga Department of Laboratory Medicine, Hebei Yanda Lu Daopei Hospital, Langfang, ChinaCorrespondence[email protected] [email protected]

Your download is now in progress and you may close this window